Skip to main content
. Author manuscript; available in PMC: 2016 Oct 26.
Published in final edited form as: Cancer Res. 2012 Jan 26;72(6):1529–1537. doi: 10.1158/0008-5472.CAN-11-2602

Figure 5.

Figure 5

PTP1B down-regulation delays tumor occurrence and decreases tumor growth rates in vivo. (A) Western immunoblotting showing PTP1B levels in stable shCTRL and shPTP1B clones (left panel) relative to Calnexin (right panel). For the xenograft assays, a total of 40 mice were injected with either shCTRL-1a (n=10), shCTRL-1b (n=10), shPTP1B-1a (n=10), and shPTP1B-2 (n=10) clones. For data analysis, shCTRL and shPTP1B mice were pooled together (B) Tumor development occurred in 15 shCTRL mice, and 13 shPTP1B animals. Kaplan-Meier analyses of tumor occurence shows that shPTP1B tumors at a median time of onset (TD50) of 9 weeks compared to 6 weeks for shCTRL clones (Log-rank test, p<0.05). (C) Weekly monitoring of tumor growth revealed that shPTP1B tumors growth significantly slower than the shCTRL tumors (Mann-Whitney test, p<0.01).